Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The Mucormycosis is previously called as zygomycosis which is a rare but lethal angio-invasive infection which is caused because of group of fungi called as mucormycetes. Spores of these ubiquitous fungi are generally seen in soil, fallen leaves, compost, animal dung and air it may be inhaled and then infect the lungs, sinuses and extend into the brain and eyes. Less frequently, infection may develop when the spores enter the body by a cut or an open wound. It is not a contagious disease i.e. it cannot spread from one person to another. Mucormycosis is an aggressive, life-threatening infection requiring quick diagnosis and early treatment.
The Asia Pacific mucormycosis market is witnessing rapid growth during forecast period of 2021 to 2027. The mucormycosis will leads to blindness, organ dysfunction and other problems which may need surgical treatment sometimes. The dynamic factors such as upsurge in the prevalence of fungal infections is propelling growth of Asia Pacific mucormycosis market. The availability of extensive variety of drugs is also boosting growth of Asia Pacific mucormycosis market. The increasing cases of immunological diseases is also refuelling growth of Asia Pacific mucormycosis market. However, presence of misbranded drugs is hampering growth of Asia Pacific mucormycosis market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the mucormycosis market. In addition, complete analysis of changes on mucormycosis expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe.
The Asia Pacific mucormycosis market is segmented into the species, diagnosis method, drugs, distribution channel and country.
The Asia Pacific mucormycosis market is comprised of species such as rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other species. The saksenaea is also contributing to the growth of Asia Pacific mucormycosis market. The saksenaea is a genus of fungi in the saksenaeaceae family. The species is firstly described in 1953, which is capable of causing severe human infections. It is characterised by the formation of flask-shaped sporangia with columellae and simple, darkly pigmented rhizoids.
The Asia Pacific mucormycosis market is comprised on diagnosis method is comprised of diagnosis methods such as magnetic resonance imaging, computed tomography, tissue biopsy and others. The computed tomography is estimated to dominate the market in 2020. The growing prevalence of fungal disease is driving growth of Asia Pacific mucormycosis market by diagnosis method. The rising technological advances is boosting growth of Asia Pacific mucormycosis market.
The Asia Pacific mucormycosis market is comprised of drugs such as Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. In which flucytosine is also contributing to the growth of Asia Pacific mucormycosis market. The rising cases of mucormycosis is propelling growth of Asia Pacific mucormycosis market. The growing cases of immune suppressant diseases is also boosting growth of Asia Pacific mucormycosis market.
The Asia Pacific mucormycosis market is comprised of distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies. In which hospital pharmacies are anticipated to dominate the market in 2020. The increasing patient footfall is propelling growth of Asia Pacific mucormycosis market. The growing rate of admission in hospital for treatment is also boosting growth of Asia Pacific mucormycosis market. The growing number of hospitals is also driving growth of Asia Pacific mucormycosis market.
The Asia Pacific mucormycosis market is studied for key countries such as India, China, Japan, Australia and South Korea. In which China followed by India and Japan are anticipated to dominate the market in 2020. The rising disposable income of countries is propelling growth of Asia Pacific mucormycosis market. The growing rate of mucormycosis is also boosting growth of Asia Pacific mucormycosis market. The growing healthcare spending is also driving growth of Asia Pacific mucormycosis market.
The major key players such as Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums And Vaccines, Bdr Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited and Tlc Pharma Labs among others.
June 2021: Celon Laboratories launched an alternative drug, Amphotericin B Emulsion for the treatment of mucormycosis.
May 2021: TLC Pharma, a clinical-stage specialty pharmaceutical company, received approval for the New Drug Application (NDA) for Amphotericin B liposome injection (AmphoTLC), form the Central Drugs Standard Control Organization (CDSCO) of India. The drug can be used in the treatment of fungal infections including mucormycosis infections.
2020: Pfizer Inc. in association with its partner Basilea Pharmaceutica Ltd., launched Cresemba (isavuconazole). The drug is used in mucormycosis and invasive aspergillosis.
September 2019: U.S. FDA granted Fast Track designations for intravenous (IV) and oral formulations for fosmanogepix (APX001) developed, by Amplyx Pharmaceuticals.
The report analyses the mucormycosis market based on species, diagnosis method, drugs, distribution channel and country. Various species of fungi covered in mucormycosis market are rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other. By diagnosis method, the market is segmented into the magnetic resonance imaging, computed tomography, tissue biopsy and other. Based on drugs the market is segmented into Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. Based on distribution channel, the market is segmented into the hospital pharmacies, retail pharmacies and online pharmacies. The report also analyses the impact of COVID-19 on the market and it concludes that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe. The report also comprised of major key players operating in the market.
Why to buy this report
